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Abstract 
We explored socioeconomic and demographic disparities in breast cancer (BC) stage at 
presentation and survival in a Swiss population-based sample of female BC patients linked to the 
census-based Swiss National Cohort. Tumour stage was classified according to Surveillance, 
Epidemiology and End Results (SEER) Program summary stage (in situ/localized/regional/distant). 
We used highest education level attained to estimate SEP (low/middle/high). Further 
demographic characteristics of interest were age at presentation (30-49/50-69/70-84 years), 
living in a canton with organized screening (yes/no), civil status 
(single/married/widowed/divorced) and nationality (Swiss/non-Swiss). We used ordered logistic 
regression models to analyse factors associated with BC stage at presentation and competing 
risk regression models for factors associated with survival. Odds of later-stage BC were 
significantly increased for low SEP women (odds ratio (OR) 1.26, 95%CI 1.12-1.41) compared to 
women of high SEP. Further, women living in a canton without organized screening programme, 
women diagnosed outside the targeted screening age and single/widowed/divorced women 
were more often diagnosed at later stages. Women of low SEP experienced an increased risk of 
dying from BC (sub-hazard ratio 1.27, 95%CI 1.14-1.43) compared to women of high SEP. 
Notably, these survival inequalities could not be explained by socioeconomic differences in stage 
at presentation and/or other sociodemographic factors. It is concerning that these social 
gradients have been observed in a country with universal health insurance coverage, high health 
expenditures and one of the highest life expectancies in the world. 
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Background 1 
Breast cancer is the most common cancer in Swiss women. In Switzerland, each year 2 
approximately 5,700 women are newly diagnosed with breast cancer and the lifetime risk of 3 
developing breast cancer is almost 13%.1 Although mortality has fallen consistently over the last 4 
30 years, breast cancer is the leading cause of cancer death in Swiss women with approximately 5 
1,400 women dying each year of this disease.1 Tumour stage at presentation remains one of the 6 
major prognostics factors and women with early-stage breast cancer are expected to have 7 
excellent survival rates. In a recent Swiss study, age-standardized 10-year relative survival varied 8 
from 9.3% (Stage IV) to 94.5% (Stage I) depending on stage at presentation.2  9 
Several studies outside of Switzerland have reported negative associations between 10 
socioeconomic position (SEP) and breast cancer stage at presentation as well as socioeconomic 11 
inequalities in survival after breast cancer diagnosis.3 Socioeconomic and demographic factors 12 
may influence access to health care4, cancer awareness5 and woman’s attitudes towards 13 
preventive methods such as mammography screening, clinical breast examination and breast 14 
self-examination.6  15 
In Switzerland, health care is organized at the cantonal level, resulting in regional differences in 16 
provision of cancer prevention and management services.7 A Swiss breast cancer pattern of care 17 
study, for example, reported considerable regional variations in early breast cancer detection 18 
and treatment.7 In western Switzerland (French-speaking part of the country), organized breast 19 
cancer screening programmes have gradually been implemented since 1999 for women aged 50 20 
to 69 years, whereas in most other regions (German and Italian-speaking parts of Switzerland) 21 
only opportunistic screening is available.8 Consequently, screening uptake varies by canton and 22 
region. The Swiss Health Survey 2012 reports that in 2010-2011, cantons with organized 23 
mammography screening had a 68% mammogram coverage of women in the recommended 24 
screening age (50-69 years), compared to 37% in cantons without an organized programme.9 25 
Organized breast cancer screening may reduce social inequalities in screening uptake10, 11, 26 
although this has not been consistently observed across countries.12 27 
Several studies have identified stage at presentation as an important factor in survival 28 
differences between socioeconomic groups.13 In most studies, however, disparities remained 29 
after adjustment for stage and other tumour and demographic characteristics.13 Remaining 30 
disparities have been associated with treatment disparities, variations in comorbidities and/or 31 
additional factors like variations in psychosocial well-being and patients’ support.13 In Geneva, 32 
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women with lower SEP were diagnosed with more advanced breast cancer, received more often 33 
suboptimal treatment and showed lower cause-specific and overall survival.14 A later study in 34 
Geneva, observed substantial social inequalities in breast cancer management including 35 
diagnostic procedures and primary treatment.15 36 
A major goal of health care systems is to equally improve the health in all groups of the 37 
population they serve.16 Despite this aim, socioeconomic and -demographic health inequalities in 38 
breast cancer detection and survival have been observed all over the world13, including countries 39 
with tax-funded health care systems designed to provide equal access to care.17, 18 40 
Swiss data on socioeconomic health inequalities in stage at presentation and survival of breast 41 
cancer in women is very limited. Therefore, the present study aimed to evaluate socioeconomic 42 
and demographic disparities in breast cancer stage at presentation and survival in a Swiss 43 
population-based sample of female breast cancer patients diagnosed between 2001 and 2008.  44 
Materials and Methods 45 
Data sources and inclusion criteria 46 
This study is based on data from the SNC-NICER Cancer Epidemiology Study. The SNC-NICER 47 
Cancer Epidemiology Study took advantage of the Swiss National Cohort (SNC) and the National 48 
Institute for Cancer Epidemiology and Registration (NICER) cancer registry network to build a 49 
comprehensive historical cohort, allowing epidemiologic analysis of factors associated with 50 
cancer incidence, mortality and survival in Switzerland.  51 
A detailed description of the SNC can be found elsewhere.19 Briefly, 1990 and 2000 census 52 
records were probabilistically linked to cause-specific mortality or emigration records from 1991-53 
2013 provided by the Federal Statistical Office (FSO). The Swiss census is mandatory and virtually 54 
complete with a 2000 census estimated coverage of 98.6%.19 This study used SNC 55 
sociodemographic information on sex, education level, marital status, place of residence and 56 
nationality at census date. The coding of the underlying cause of death is federally standardised 57 
by the FSO. Since 1995, the 10th revision of the international classification of diseases and related 58 
health problems (ICD-10) has been used following international standards.  59 
In Switzerland, cancer registration is primarily organized at the cantonal level. The earliest cancer 60 
registry (CR) data is available from Geneva dating back to 1970, followed by Vaud and Neuchâtel 61 
(1974), Zurich (1980), St. Gallen-Appenzell (1980), Basel-Stadt and Basel-Landschaft (1981), 62 
Valais (1989), Graubünden (1989), Glarus (1992), Ticino (1996), Jura (2005) and Fribourg (2006). 63 
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More recently, cancer registration has been introduced in Lucerne (2010), Nidwalden, 64 
Obwalden, Uri, Zug (2011), Thurgau (2012), Aargau (2013) and Bern (2014). All CRs implemented 65 
before 2008 have been requested to participate in the SNC-NICER Cancer Epidemiology Study. 66 
Seven out of eleven CRs eligible for the study, agreed to participate and provided incidence data 67 
to the pooled dataset: Fribourg, Geneva, Neuchâtel, Ticino, Valais, Vaud and Zurich. Data from 68 
these CRs were probabilistically linked to the SNC, including all incident cases starting from the 69 
date of the census 1990 (or from the implementation of cantonal cancer registration if later) 70 
through the end of 2008. In 2008, these cantons covered 46.1% of the Swiss population. To 71 
assess sample representativeness, we compared frequency distributions (age, civil status, 72 
education, urbanity of residence and nationality) between female residents of participating 73 
countries and whole of Switzerland using census 2000 information. Compared to total 74 
Switzerland, the participating cantons showed distinctly higher proportions of women with 75 
tertiary education (16.8% versus 11.1%), women living in urban and peri-urban areas (35.3% 76 
versus 24.7% and 48.8% versus 41.2%, respectively), and women with foreign nationality (22.7% 77 
vs.15.5%). Cancer registration data used in this study included sex, date of birth, date of cancer 78 
diagnosis, basis of diagnosis, topography, morphology and behaviour of the tumour, and 79 
Tumour, Node and Metastasis staging information (TNM).  80 
The current study population included 17,298 female breast cancer cases (carcinoma in situ and 81 
invasive breast cancer) first diagnosed between Census 2000 (5th of December 2000) and 31st of 82 
December 2008. TNM codes were based on the fifth and sixth TNM editions. The Census 2000 83 
was used as starting point as for previous time periods, the proportion of missing stage 84 
information was high (up to >25%) in two cantons. Education was used as a proxy for SEP so 85 
young women (< 30 years of age at diagnosis, N=46) and women with missing education 86 
information (N=147) were excluded from the study population. In addition, women diagnosed at 87 
85 years of age or older were excluded (N=936) because data quality (percentage of death 88 
certificate only cases [%DCO] 8.2%, histologically verified cases 78.4%) and completeness of 89 
stage information (60.1%) was low in this age group. The study population showed %DCO of 90 
0.4% indicating high completeness of case ascertainment with 98.3% of the cases histologically 91 
verified and 94.8% with sufficient TNM information to classify tumour stage.  92 
Stage at presentation analyses were based on data from a subset of cantonal cancer registries 93 
(Geneva, Valais, Zurich) that provided breast carcinoma in situ cases (N=10,915). In a 94 
supplemental analysis, stage at presentation calculations were repeated and limited to invasive 95 
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breast cancers to enable the inclusion of all participating cancer registries (Suppl. Table 1). The 96 
supplemental analysis followed survival analyses were based on invasive cancers including all 97 
participating cancer registries (16,296). 98 
Analytic methods 99 
Surveillance, Epidemiology and End Results (SEER) Program summary stage was calculated based 100 
on the TNM classification system following the algorithm for mapping stage at diagnosis from 101 
TNM to SEER summary stage as described by Walters et al.20 We used SEER summary stage 102 
instead of the more detailed TNM staging system due to extensive and significant revision in 103 
breast cancer staging between the fifth and sixth TNM edition.  104 
We prioritized pathological T and N over clinical T and N. Missing M or Mx were assumed to be 105 
equivalent to M0. If clinical and pathological M was available, any indication of metastasis was 106 
prioritized. Pathological and clinical T and N information was available in 84.1% and 46.0% of all 107 
invasive breast cancer cases, respectively. The proportion of cases with missing M or Mx was 108 
26.4%. Overall, tumour stage could be calculated for 94.9% of all invasive breast cancer cases. 109 
Carcinoma in situ cases have been identified based on the ICD-O-3 behaviour code.  110 
We used highest education level attained by the woman to estimate SEP (compulsory education 111 
or less: low SEP, secondary education: middle SEP, tertiary education: high SEP).  112 
We descriptively investigated stage at presentation by SEP, age-group (30-49, 50-69, 70-84 113 
years) and residence (canton with or without organized screening). Ordered logistic regression 114 
models examined the association between cancer stage at presentation and SEP. We calculated 115 
three models using the following variables as predictors for stage at presentation: (model 1) SEP; 116 
(model 2) model 1 plus age at presentation (30-49, 50-69, 70-84 years), civil status (30-49, 50-69, 117 
70-84 years) and nationality (Swiss, non-Swiss); (model 3) model 2 plus urbanity of residence and 118 
canton with or without organized screening programme. The third model has been additionally 119 
adjusted for canton of residence. No significant interactions were observed, therefore, we only 120 
included main effects in the final model.  121 
For women within the recommended screening age, we conducted a sub-analysis of Valais and 122 
Geneva, the only two cantons which both, offered organized screening during the study period 123 
and provided carcinoma in situ cases to the study population. We examined the association 124 
between being diagnosed within or outside the organized programme and SEP using logistic 125 
regression including civil status and nationality and canton of residence as covariates. 126 
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Survival was analysed using competing risk regressions based on Fine and Gray's proportional 127 
hazard model.21 All underlying causes of death other than breast cancer were classified as 128 
competing risks. Four models have been calculated using the following variables as predictors: 129 
(model 1) SEP; (model 2) model 1 plus age at presentation, civil status and nationality; (model 3) 130 
model 2 plus stage at presentation; and (model 4) model 3 plus urbanity of residenc and canton 131 
with or without organized screening programme. Results of survival analyses are reported as sub-132 
hazard ratios of death due to breast cancer (SHRs) with 95% confidence intervals (95%CI).  133 
Both final models (stage at presentation and survival analyses) have been additionally adjusted 134 
for canton of residence to account for unmeasured canton characteristics associated with SEP 135 
distribution and stage at diagnosis/survival.   136 
All analyses were performed using the statistical software package Stata, version 13.1 for 137 
Windows (StataCorp, College Station, Texas). 138 
Results 139 
Patient characteristics by SEP cases included in stage at presentation and survival analyses are 140 
listed in Table 1. Incident breast carcinoma cases (Ntotal=10,915, Nstaged=10,362) by cancer 141 
registry included in stage at presentation analyses is shown in Suppl. Table 2. Incident breast 142 
cancer cases (Ntotal=16,296; Nstaged=15,462) and person-years (PY) (PYstotal=127,040; 143 
PYstaged=121,553) by cancer registry included in survival analyses is shown in Suppl. Table 3.  144 
Breast cancer stage at presentation 145 
In the unadjusted model, odds ratios (ORs) of later stage at breast cancer diagnosis were 146 
significantly increased for women of middle (OR 1.18, 95%CI 1.07-1.31) and low SEP (OR 1.30, 147 
95%CI 1.16-1.46) compared to women of high SEP (Table 2). After adjustment for demographic 148 
factors (model 2) and area of living (urbanity of residence, canton with/without organized 149 
screening, canton of living) (model 3), ORs for middle SEP women and low SEP women decreased 150 
to 1.09 (95%CI 0.99-1.21) and 1.19 (95%CI 1.06-1.34), respectively. In the final model, women 151 
living in a canton without an organized screening programme were also more likely to have their 152 
breast cancer diagnosed at a later stage (OR 1.42, 95%CI 1.30-1.55). Further, women outside the 153 
targeted screening age (30-49 years: OR 1.22, 95%CI 1.11-1.33; 70-84 years OR: 1.31, 95%CI 154 
1.19-1.45) and single/widowed/divorced women showed elevated risks for later stages at 155 
diagnosis (OR 1.12 (95%CI 0.99-1.27) - 1.14 (95%CI 1.02-1.27)).  156 
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We observed higher proportions of early stage breast cancer (carcinoma in situ and localized 157 
cancers) in cantons with organized breast cancer screening compared to the canton without 158 
organized screening (Figure 1). In the recommended screening age-group (50-69 years), the 159 
observed proportion of early stage breast cancer (carcinoma in situ and localized breast cancer) 160 
was 64.7% vs. 51.9% (low SEP), 65.0% vs. 57.0% (middle SEP), and 69.4% vs. 56.6% (high SEP). A 161 
similar tendency towards higher proportions of early stage breast cancer in cantons with 162 
organized screening (regardless of SEP) was also observed in the age-group 70-84 years. 163 
However, due to comparably high number of cases without stage information, i.e. in the canton 164 
without organized screening, figures for this age-group are difficult to interpret. In women aged 165 
30-49 years, early stage detection in women varied across SEPs between 56.9% (middle SEP) and 166 
59.5% (high SEP) in cantons with organized screening and 50.0% (middle SEP) and 53.3% (high 167 
SEP) in the canton without organized screening. 168 
When looking at carcinoma in situ cases in women in the recommended screening age-group, 169 
only women living in a canton with organized screening programme showed a social gradient 170 
with 9.3%, 11.9% and 15.0% of carcinoma in situ cases for low, middle and high SEP women, 171 
respectively. In the canton without organized screening, the proportion of carcinoma in situ 172 
cases were fairly stable with 8.5% (low SEP), 9.8% (middle SEP) and 8.2% (high SEP). 173 
In cantons with organized programmes, 16% (canton Geneva) and 32% (canton Valais) of 174 
diagnosed breast cancer cases in the age-group eligible for organized breast cancer screening 175 
were detected within the framework of an organized programme. Compared to women with 176 
high SEP, women with middle (OR 1.25, 95%CI 1.03-1.53) and low SEP (OR 1.39, 95%CI 1.11-1.73) 177 
were more likely to be diagnosed outside of the organized screening programme.  178 
Breast cancer survival 179 
Stage information was lacking in 5.1% (Table 1). Of the 16,296 incident cases included in the 180 
survival analyses, 3,713 cases died before the end of follow-up (22.8%) and 229 (1.4%) were lost-181 
to-follow-up.  182 
In all models, diagnosed women with low SEP were more likely to die of breast cancer compared 183 
to women with high SEP (Table 3). SHRs of low SEP women gradually decreased from 1.60 184 
(95%CI 1.40-1.83, model 1) to 1.22 (95% CI 1.05-1.43, model 4) after adjustment for further 185 
demographic factors (model 2), stage at presentation (model 3) and area of living (canton 186 
with/without organized screening, canton of living, model 4). In the fully adjusted model (model 187 
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4), later stage at presentation was strongly associated with an increased risk of breast cancer 188 
death (regional stage: SHR 4.12, 95%CI 3.66-4.63; distant stage: SHR 27.27, 95%CI 23.67-31.41). 189 
Compared to women diagnosed in the recommended screening age (50-69 years), women aged 190 
70-84 years showed an elevated risk of breast cancer death (SHR 1.34, 95%CI 1.19-1.50). For 191 
women aged 30-49 years, a reduced risk was observed (SHR 0.76, 95%CI 0.66-0.86). Living in a 192 
canton without an organized screening was associated with an increased SHR (SHR 1.44, 95%CI 193 
1.23-1.68) even after adjustment for stage at diagnosis. Further, living in a non-urban region was 194 
associated with an increased risk of breast cancer death with SHRs of 1.13 (95%CI 1.02-1.26) 195 
(peri-urban region) and 1.21 (95%CI 1.03-1.41) (rural region). Residents of foreign nationality 196 
were at lower risk of dying from their breast cancer (SHR 0.84, 95%CI 0.73-0.98). We observed 197 
no statistically significant effects for civil status in the fully adjusted model (Table 3).  198 
Discussion 199 
Summary of main findings 200 
Despite universal health insurance coverage22, high health expenditures22, the highest average 201 
household net financial wealth worldwide23 and one of the highest life expectancies in the 202 
world24, high risk groups for later-stage breast cancer and lower breast cancer survival were 203 
identified in Switzerland. In our study, women of lower SEP, unmarried women, women below 204 
(<50 years) or above (>69 years) the recommended screening age, and women living in a canton 205 
with no organized breast cancer screening programme showed an increased risk of being 206 
diagnosed with a later-stage breast cancer. In addition, women of lower SEP experienced poorer 207 
disease-specific survival. Notably, these survival inequalities could not be explained by 208 
socioeconomic differences in stage at presentation and/or other sociodemographic factors such 209 
as age, nationality and civil status. 210 
Discussion in the context of the literature 211 
Our Swiss results are in line with international data, showing that lower SEP is associated with 212 
later-stage breast cancer and shortened survival.3 Much of the deprivation gap in survival can be 213 
attributed to inequalities in stage at presentation, the most important single predictor for breast 214 
cancer survival.13, 25 However, in most research socioeconomic survival gaps remained in stage-215 
stratified analyses or after adjustment for stage at diagnosis.13, 25 Further, socioeconomic 216 
inequalities for breast cancer stage and survival were observed in various countries irrespective 217 
of the measurement used for SEP classification (e.g. education, occupation, income, area-based 218 
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deprivation index).13 Possible reasons for the delayed breast cancer diagnosis in lower SEP 219 
women might be related to inequalities in health care access4, cancer awareness5 and/or 220 
attitudes towards cancer (e. g. cancer fatalism).6 All these factors might substantially contribute 221 
to observed disparities in breast cancer screening uptake11, 26, and/or cancer-related health 222 
behaviour such as health care seeking after detection of first symptoms (patient-mediated 223 
delay).27 Essentially, equal access to health care goes beyond universal health insurance 224 
coverage and adequate provision of accessible health services (such as provision in proximity of 225 
the patient's residence).28 Additional factors such as language barriers, uncovered costs (travel 226 
costs, childcare during consultation/treatment) or previous negative health care experiences 227 
might hamper health care access of individuals and specific social groups.29 Disparities in cancer 228 
awareness might have also influenced the results. In a Danish study, for example, lower SEP was 229 
associated with less awareness of breast cancer symptoms and risk factors.5 Further, fatalistic 230 
attitudes towards cancer have been shown to be associated with lower SEP6, 30, whereas cancer 231 
fatalism in turn was associated with being less positive about early detection and being more 232 
fearful about seeking help for suspicious symptoms.30 In our study, we observed a social shift 233 
towards higher proportions of carcinoma in situ cases for women in the recommended screening 234 
age only in cantons offering organized screening. In the canton without organized screening, 235 
proportions of carcinoma in situ cases were fairly equal across SEP groups, similar to those 236 
observed in low SEP women in cantons with organized screening. As carcinoma in situ are rare in 237 
the symptomatic setting, observed variations were most likely caused by differences in 238 
mammography screening use (organized and/or opportunistic). In the canton without organized 239 
screening programme, social inequalities in early detection were mainly visible for localized 240 
breast cancer indicating that in this canton other factors such as inequalities in cancer 241 
awareness/knowledge, health care access and /or help seeking behaviour after detection of 242 
symptoms might have led to the observed results.  243 
In our study, socioeconomic inequalities in survival remained after adjusting for stage at 244 
presentation suggesting that further factors such as treatment disparities and/or variations in 245 
comorbidities might play a role. This assumption is supported by the findings in the canton of 246 
Geneva, where lower SEP women were more likely to receive suboptimal treatment compared 247 
to their more affluent counterparts.14, 15  248 
In women aged 70-84 years, lower SEP was associated with an increased proportion of unstaged 249 
breast cancers. However, a clear social gradient was only apparent in the cantons with organized 250 
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screening programmes. Women 85 years and older were excluded from the analyses because of 251 
the high proportion with missing stage information despite the fact that tumour stage should be 252 
investigated (at least clinically) in all women with breast cancer.31 However, a distinction must be 253 
made between a true lack of stage information and a lack of reporting stage.32 A true lack of 254 
staging might occur in patients with very limited life expectancy (severe comorbidities, high 255 
age)32, 33 or due to patients’ choice.32, 34 In contrast, lack of reporting refers to cases where 256 
clinical and/or pathological stage has been investigated but has not been captured by the cancer 257 
registry. A study investigating the completeness of breast cancer staging in the New Zealand 258 
Cancer Registry, found that 12% of staged breast cancer cases were recorded as unknown stage 259 
in the cancer registry system.32 Although observed socioeconomic inequalities in diagnostic 260 
assessment might be – at least partly – explained by the fact that comorbidities are more 261 
common in lower SEP women and in older women.35  262 
Biennial mammography coverage in the recommended screening age was substantially higher in 263 
cantons with an organized programme (located in the western, French-speaking region of 264 
Switzerland) compared to cantons without organized programme.9 However, the participation 265 
rate in the organized programmes varied substantially across cantons. In 2004, screening 266 
coverage in the organized programme of women aged 50-69 years was 23% in Geneva compared 267 
to 66% in Valais.36 Importantly, opportunistic screening has widely been offered concomitantly 268 
to organized programmes in Switzerland.36 A prospective study in Geneva reported that only 269 
12% of women invited to screening were screened within the organized programme and 39% 270 
received screening outside of the framework of the organized programme.10 Therefore, the 271 
lower participation rate in the Geneva programme likely reflects a higher prevalence of 272 
opportunistic screening rather than real differences in mammography coverage.37  273 
In our analyses, the cantons with organized breast cancer screening programmes showed a shift 274 
towards earlier stages in women aged 50 years and older compared to the canton without an 275 
implemented programme. A similar shift – albeit less pronounced – has been observed for 276 
younger women below the recommended screening age indicating that younger women in 277 
cantons with organised screening are more likely to undergo mammography screening than their 278 
counterparts in cantons without a programme.  279 
Women outside the recommended screening age showed an increased risk of being diagnosed 280 
at later stages. For the time period under investigation, the recommended screening age in 281 
Switzerland was 50-69 years. The age-cut was based on the fact that at this time the most 282 
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convincing evidence for a beneficial effect available from randomized controlled trials existed for 283 
women aged 50-69 years. However, women older than 69 years were allowed to continue 284 
screening within the organized program if desired and if no major comorbidities existed.36 285 
Diagnosing breast cancer by mammography is more difficult in younger women because their 286 
breast tissue is denser making it hard to detect anomalies - the main reason why mammography 287 
screening is not recommended for younger women.36 Breast cancer in younger women has been 288 
shown to be more aggressive38 and have a less favourable prognosis39, although the latter has 289 
not been consistently observed.40 In our study, we observed an increased survival for women 290 
below the age of 50 years compared to their older counterparts (overall and adjusted for stage 291 
at presentation). An earlier Swiss study found that women with breast cancer diagnosed below 292 
the age of 40 years had substantially lower survival than women diagnosed between the age of 293 
40-49 years.39 Due to the small number of cases below the age of 40 years we categorised 294 
younger women as < 50 years thus potential survival disadvantages in the very young women 295 
could not be examined in this study.  296 
Several studies outside of Switzerland observed beneficial impacts of being married in regard to 297 
breast cancer stage at presentation and survival after breast cancer13, 41, indicating that social 298 
support might have a significant impact on cancer detection, treatment and survival.41 A study in 299 
the United States observed that unmarried women were at higher risk of being diagnosed with 300 
metastatic cancer, under-treatment and death resulting from their cancer.41 In our study, we 301 
observed an increased risk for unmarried women for being diagnosed with later stage breast 302 
cancer (albeit not reaching significance for widowed women). For survival after breast cancer, 303 
we observed a significantly lower survival only in single women and only if not adjusted for stage 304 
at diagnosis. In this study marital status was obtained from the census and with increasing time 305 
between date of census and end of follow-up, marital status might have changed leading to 306 
misclassification when referring to the time of or after diagnosis.  307 
In our study, women living in non-urban regions showed lower survival compared to their urban 308 
counterparts. Factors that may mediate these disparities may include inequalities in tumour 309 
characteristics (i.e. stage at presentation), patients’ treatment preferences and adherence, 310 
and/or access to and quality of care received. However, in our study we did not observe 311 
significant disparities in stage at presentation between the rural and urban population 312 
suggesting that differences in early-detection played a minor role.  313 
Published in final edited form as: Int J Cancer. 2017 Oct 15;141(8):1529-1539. doi: 10.1002/ijc.30856 
13 
 
Compared to women with Swiss nationality, our results suggest that women of foreign 314 
nationality have an overall and stage-specific survival benefit. A potential explanation for these 315 
differences is the so-called “healthy migrant effect”. The healthy migrant effect describes an 316 
empirically observed mortality advantage of migrants relative to the population in the host 317 
country due to self-selection of migrants who tend to differ from their fellow countrymen in 318 
respect to education, risk exposure or health, leading to better health outcomes despite 319 
potential social inequalities and discrimination in the host country. However, data quality issues 320 
might have affected the results in this study. Death records of non-Swiss residents showed an 321 
increased probability of not being linked to census data compared to death records of Swiss 322 
nationals19 and (undocumented) out-migration may have led to incomplete mortality follow-up, 323 
especially in semi-skilled or unskilled migrant workers, who tend to leave the home country 324 
when they are sick or disabled.42 Additionally, it is difficult to draw conclusions for the non-Swiss 325 
population because it is a highly heterogeneous group. Non-Swiss have different countries of 326 
origin, migration status (first, second or third generation immigrants), type of residence permit, 327 
level of education, employment and income, to name a few. Hence, this topic should be 328 
investigated further in future studies.  329 
Strengths and Limitations 330 
This is the first Swiss study investigating socioeconomic inequalities of breast cancer stage at 331 
presentation and survival, combining data from multiple Swiss cantons and from a national 332 
census. Overall, the study population had less than 0.5% DCO cases indicating a high 333 
completeness of case ascertainment. In the age-group under investigation, stage information 334 
was available for 95% of all cases. 335 
Our study has some limitations.  First,  the meaning and consequences of educational attainment 336 
might vary by birth cohort.43 However, there is considerable international evidence that 337 
education is strongly associated with health, health behaviour and preventive service use and 338 
that a substantial share of these effects are of causal origin.44 In addition, individual education is 339 
generally stable beyond early adulthood whereas civil status and living conditions are more likely 340 
to change over time and individual education level was virtually complete (>99%) in the study 341 
population. In a preceeding analysis, we compared three indicators of SEP in relation to stage at 342 
presentation: (1) education woman - highest education level attained by the woman 343 
(compulsory or less, upper-secondary, upper-tertiary education), (2) education couple – if 344 
married, highest education level attained by the woman or spouse, and (3) quintiles of the Swiss 345 
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neighbourhood index (Swiss-SEP), a composite area-level SEP measure based on income, 346 
education, occupation and housing conditions.45 Regardless of SEP indicator used, we observed 347 
comparable patterns and effects for SEP and the covariates (age, civil status, residence in a 348 
canton with or without screening programme, nationality) included in the models46, although 349 
importantly, each indicator of SEP measures different aspects of socioeconomic stratification 350 
and may be more or less relevant to different health outcomes.43 351 
Overall, only 7 out of 26 Swiss cantons participated in the study covering around 46% of the 352 
population. Further, stage at presentation analyses were restricted to cantonal cancer registries 353 
providing carcinoma in situ cases diminishing population coverage for these analyses to 27%. The 354 
resulting study sample was not representative for the female Swiss population with respect to 355 
SEP, urbanity or residence and nationality. Importantly, there may be also other unmeasured 356 
cantonal/regional characteristics associated with stage at presentation and/or survival that could 357 
impact the results. Therefore, we additionally adjusted for canton of residence in the final 358 
models. Generalisability of these finding, although better than previous publications, remains 359 
limited by the lack of cantonal cancer registry participation and should be made with caution. 360 
Another weakness of the study is the lack of more detailed tumour characteristics (morphologic 361 
subtype, grade, oestrogen receptor (ER) status, progesterone-receptor (PR) status, human 362 
epidermal growth factor receptor 2 (HER2/neu) status) and other prognostic factors such as 363 
comorbidities and cancer treatment. From studies outside of Switzerland, it is known that 364 
morphological type of breast cancer and ER status might vary between social groups.13 A Swiss 365 
study conducted in Geneva reported variations depending on SEP for stage at presentation and 366 
morphological breast cancer type, but not for grade, tumour size and ER status.14 Substantial 367 
treatment differences between social groups have been also been reported for this canton.14, 15 368 
Additional analysis of morphological type by SEP (not presented) suggests that morphological 369 
differences reported from Geneva might be largely the result of varying proportions of cases 370 
with unknown morphological type (classified as other morphological type in their analyses) 371 
rather than reflecting real morphological differences between social groups. Further, stage at 372 
presentation has been consistently shown to be a major predictor of breast cancer survival and 373 
other tumour characteristics contributed much less to the explanation of the observed survival 374 
experience.13  375 
Comorbidities are more common in lower SEP women and may have an adverse impact on 376 
cancer survival.35 Comorbidities might be associated with less complete diagnostic assessment 377 
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including biopsy for staging32, 33, limited treatment options, and a decreased likelihood to receive 378 
treatment with curative intent47. Further, SEP might influence patients treatment choice48 379 
and/or adherence to treatment49. However, studies of Geneva suggest that observed survival 380 
inequalities after breast cancer are – at least partly – caused by differences in care management 381 
depending on SEP.14, 15 Unfortunately, information on comorbidities were not available for this 382 
study.  383 
Since the introduction of breast cancer screening programmes, the usefulness of mammography 384 
screening has been questioned. Critics argue that screening-induced over-diagnosis and its 385 
consequences outbalance potential mortality benefits.50 Consequently, our analyses might be 386 
affected by higher proportions of over-diagnosis in the cantons with implemented screening 387 
programme resulting in higher mammography screening coverage. 388 
Finally, we used the SEER basic summary staging because substantial TNM classification changes 389 
over the investigated time period prevented the use of the more detailed TNM-staging. A more 390 
detailed staging system might have shown stronger effects. 391 
Conclusions 392 
Characteristics associated with later stage breast cancer diagnosis in Switzerland were lower SEP, 393 
being unmarried, being outside of the recommended screening age and living in a canton 394 
without an organized breast cancer screening programme. In addition, women of lower SEP 395 
experienced poorer disease-specific survival. Notably, these survival inequalities could not be 396 
explained by socioeconomic differences at stage of presentation and/or other sociodemographic 397 
factors such as age, nationality and civil status. Appropriate intervention strategies are needed 398 
to reduce socioeconomic and demographic health inequalities in women with breast cancer. 399 
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Table 1: Patient characteristics by socioeconomic position (SEP). (1) Carcinoma in situ and invasive breast 
cancer cases from three Swiss cancer registries (CRs) for stage at presentation analyses. (2) Invasive 
breast cancer cases from seven Swiss cancer registries (CRs) for survival analyses. 
Analysis of SEP and 
stage at presentation 
Low SEP    Middle SEP High SEP Total 
N column %          N column %          N column %       N column %          
(1) Stage at presentation analyses (N=10,915)     
Stage at presentation 
in situ 217 7.3 574 9.6 211 11.0 1,002 9.2 
Local 1,382 46.3 2,780 46.3 951 49.4 5,113 46.8 
Regional 1,036 34.7 2,139 35.6 625 32.5 3,800 34.8 
distant 142 4.8 239 4.0 66 3.4 447 4.1 
unknown stage 206 6.9 275 4.6 72 3.7 553 5.1 
Age at presentation 
<50 years 435 14.6 1,340 22.3 590 30.7 2,365 21.7 
50-69 years 1,433 48.0 3,296 54.9 1,090 56.6 5,819 53.3 
69-84 years  1,115 37.4 1,371 22.8 245 12.7 2,731 25.0 
Living in an region with organized breast cancer screening 
Yes1 1,457 48.8 1,990 33.1 994 51.6 4,441 40.7 
No2 1,526 51.2 4,017 66.9 931 48.4 6,474 59.3 
Civil status 
single 242 8.1 750 12.5 388 20.2 1,380 12.6 
married 1,766 59.2 3,785 63.0 1,146 59.5 6,697 61.4 
widowed 638 21.4 632 10.5 115 6.0 1,385 12.7 
divorced 337 11.3 840 14.0 276 14.3 1,453 13.3 
Nationality 
Swiss  2,270 76.1 5,455 90.8 1,548 90.8 9,273 85.0 
non-Swiss 713 23.9 552 9.2 377 9.2 1,642 15.0 
         
Total      N     row % 2,983 27.3 6,007 55.0 1,925 17.6 10,915 100.0 
(2) Survival analysis (N=16,296)       
Stage at presentation 
Local 2,507 51.4 4,633 53.4 1,535 56.1 8,675 53.2 
regional 1,778 36.5 3,254 37.5 982 36.0 6,014 36.9 
Distant 267 5.5 396 4.6 110 4.0 773 4.7 
unknown stage 326 6.7 400 4.6 108 4.0 834 5.1 
Age at presentation 
<50 years 608 12.5 1,958 22.6 818 29.9 3,384 20.8 
50-69 years 2,252 46.2 4710 54.2 1,566 57.3 8,528 52.3 
70-84 years  2,018 41.4 2,015 23.2 351 12.8 4,384 26.9 
Living in a canton with organized breast cancer screening 
Yes3 2,600 53.3 3,828 44.1 1,588 58.1 8,016 49.2 
No4 2,278 47.7 4,855 55.9 1,147 41.9 8,280 50.8 
Civil status 
Single 387 7.9 1,115 12.8 527 19.3 2,029 12.5 
Married 2,838 58.2 5,483 63.2 1,659 60.6 9,980 61.2 
widowed 1,106 22.7 918 10.6 175 6.4 2,199 13.5 
divorced 547 11.2 1,167 13.4 374 13.7 2,088 12.8 
Nationality 
Swiss  3,788 77.7 7,878 90.7 2,211 80.8 13,877 85.2 
non-Swiss 1,090 22.4 805 9.3 524 19.2 2,419 14.8 
Vital status at end of follow-up 
Alive 3,277 67.2 6,819 78.5 2,258 82.6 12,354 75.8 
Dead 1,510 31.0 1,780 20.5 423 15.5 3,713 22.8 
lost-to-follow-up 91 1.9 84 1.0 54 2.0 229 1.4 
         
Total      N     row % 4,878 29.9 8,683 53.3 2,735 16.8 16,296 100,0 
Note: For stage analyses, 92 cases (0.8%) out of originally 11,007 cases have been excluded due to missing SEP information. For survival analyses 147 cases (0.9%) out of originally 
16,516 cases have been excluded due to missing SEP information. From the remaining dataset, 73 additional cases were excluded due to zero survival time (death certificate only 
cases or cases first diagnosed at autopsy). 
1Geneva, Valais; 2Zurich; 3Fribourg, Geneva, Valais, Vaud; 4Neuchâtel, Ticino, Zurich. In Neuchâtel, an organized screening programme was implemented in 2007. Incident cases of 
the years 2007 and 2008 were excluded from analyses.  
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Figure 1: Distribution of breast cancer stage at presentation by socioeconomic position (SEP), age-group and canton of 
residence (canton with organized mammography screening: Geneva, Valais; canton without organized mammography 
screening: Zurich). 
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Table 2: Odds ratio (OR) of later stage at breast cancer at presentation: Carcinoma in situ and invasive breast cancer 
cases from three Swiss cancer registries (CRs)  
 
 Model 1 Model 2 Model 3 
 OR [95%CI] OR [95%CI] OR [95%CI] 
       
SEP       
High SEP (ref.)       
Middle SEP 1.18 [1.07-1.31] 1.17 [1.05-1.29] 1.09 [0.99-1.21] 
Low SEP 1.30 [1.16-1.46] 1.25 [1.12-1.41] 1.19 [1.06-1.34] 
       
Age at presentation       
50-69 years (ref.)       
30-49 years   1.24 [1.13-1.36] 1.22 [1.11-1.33] 
70-84 years   1.41 [1.27-1.55] 1.31 [1.19-1.45] 
       
Civil status       
married (ref.)       
single   1.14 [1.01-1.27] 1.13 [1.01-1.27] 
widowed   1.13 [1.00-1.28] 1.12 [0.99-1.27] 
divorced   1.18 [1.06-1.32] 1.14 [1.02-1.27] 
       
Nationality       
Swiss (ref.)       
Non-Swiss   0.97 [0.87-1.07] 0.97 [0.88-1.08] 
       
Urbanity       
urban (ref.)       
peri-urban     0.93 [0.86-1.01] 
rural     0.98 [0.84-1.14] 
       
Organized screening1       
yes (ref.)       
no     1.42 [1.30-1.55] 
Three models have been calculated using the following variables as predictors: (model 1) SEP; (model 2) model 1 plus age at presentation, civil 
status and nationality; (model 3) model 2 plus canton with or without organized screening programme. The third model has been additionally 
adjusted for canton of residence. 
1Cantons with organized screening: Geneva, Valais; canton without organized screening: Zurich.  
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Table 3: Subhazard ratios and 95% confidence intervals (95%CI), competing risk survival after breast 
cancer in Swiss women 
 Model 1 Model 2 Model 3 Model 4 
 SHR [95%CI] SHR [95%CI] SHR [95%CI] SHR [95%CI] 
         
SEP         
High SEP (ref.)         
Middle SEP 1.20 [1.06-1.37] 1.13 [0.99-1.29] 1.06 [0.92-1.22] 1.01 [0.88-1.16] 
Low SEP 1.60 [1.40-1.83] 1.39 [1.21-1.61] 1.29 [1.11-1.50] 1.22 [1.05-1.43] 
         
Age at 
presentation 
        
50-69 years 
(ref.) 
        
30-49 years   0.84 [0.74-0.95] 0.77 [0.67-0.87] 0.76 [0.66-0.86] 
70-84 years   1.48 [1.33-1.64] 1.31 [1.17-1.47] 1.34 [1.19.1.50] 
         
Civil status         
married (ref.)         
single   1.24 [1.09-1.42] 1.14 [0.99-1.31] 1.16 [1.00-1.33] 
widowed   1.10 [0.97-1.25] 1.09 [0.95-1.26] 1.09 [0.94-1.26] 
divorced   1.02 [0.89-1.17] 0.94 [0.82-1.09] 0.97 [0.83-1.12] 
         
Nationality         
Swiss (ref.)         
Non-Swiss   0.82 [0.72-0.94] 0.80 [0.69-0.92] 0.84 [0.73-0.98] 
         
Stage at 
presentation 
        
local (ref.)         
regional     4.21 [3.75-4.74] 4.12 [3.66-4.63] 
distant     26.92 [23.39-30.98]] 27.27 [23.67-31.41] 
         
Urbanity         
urban (ref.)         
peri-urban       1.13 [1.02-1.26] 
rural       1.21 [1.03-1.41] 
         
Organized 
screening 
        
yes (ref.)         
no       1.44 [1.23-1.68] 
Survival was analysed using competing risk regressions based on Fine and Gray's proportional hazard model 21. All underlying causes of death 
other than breast cancer were classified as competing risks. Four models have been calculated using the following variables as predictors: (model 
1) SEP; (model 2) model 1 plus age at presentation, civil status and nationality; (model 3) model 2 plus stage at presentation; and (model 4) 
model 3 plus canton with or without organized screening programme. The fourth model has been additionally adjusted for canton of residence. 
Results are reported as sub-hazard ratios for breast cancer survival (SHRs) with 95% confidence intervals (95%CI).  
1Cantons with organized screening: Fribourg, Geneva, Valais, Vaud;  cantons without organized screening: Neuchâtel, Ticino, Zurich. In Neuchâtel, 
an organized screening programme was implemented in 2007. Incident cases of the years 2007 and 2008 were excluded from analyses.  
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Suppl. Table 1: Odds ratio (OR) of later breast cancer stage at at presentation: invasive breast cancer cases from seven Swiss 
cancer registries (CRs). 
 Model 1 Model 2 Model 3 
 OR [95%CI] OR [95%CI] OR [95%CI] 
       
SEP       
High SEP (ref.)       
Middle SEP 1.11 [1.01-1.21] 1.11 [1.02-1.22] 1.07 [0.98-1.17] 
Low SEP 1.16 [1.06-1.28] 1.17 [1.06-1.29] 1.15 [1.04-1.27] 
       
Age at presentation       
50-69 years (ref.)       
30-49 years   1.32 [1.22-1.43] 1.31 [1.21-1.42] 
70-84 years   1.20 [1.11-1.30] 1.21 [1.11-1.32] 
       
Civil status       
married (ref.)       
single   1.10 [1.00-1.21] 1.08 [0.98-1.19] 
widowed   1.03 [0.93-1.15] 1.02 [0.92-1.13] 
divorced   1.07 [0.98-1.18] 1.06 [0.97-1.17] 
       
Nationality       
Swiss (ref.)       
Non-Swiss   1.00 [0.91-1.09] 1.01 [0.93-1.11] 
       
Urbanity       
urban (ref.)       
peri-urban     0.95 [0.89-1.02] 
rural     1.06 [0.96-1.19] 
       
Organized screening1       
yes (ref.)       
no     1.45 [1.31-1.60] 
Three models have been calculated using the following variables as predictors: (model 1) SEP; (model 2) model 1 plus age at presentation, civil 
status and nationality; (model 3) model 2 plus canton with or without organized screening programme. The third model has been additionally 
adjusted for canton of residence. 
1Cantons with organized screening: Fribourg, Geneva, Valais, Vaud; cantons without organized screening: Neuchâtel, Ticino, Zurich. In Neuchâtel, 
an organized screening programme was implemented in 2007. Incident cases of the years 2007 and 2008 were excluded from analyses 
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Suppl. Table 2: Contribution of carcinoma in situ and invasive breast cancer cases from three Swiss cancer 
registries (CRs) to the pooled dataset to investigate the association between socioeconomic position and 
stage at presentation, incidence period 05/12/2000 - 31/12/2008  
CR 
 
 
All cases 
  Cases with stage 
information 
Cases 
(N) 
% of 
pooled 
dataset 
  
Cases 
(N) 
% of 
pooled 
dataset 
Geneva (a) 2,827 26.0   2,721 26.3 
Valais (a) 1,614 14.8   1,547 14.9 
Zurich (b) 6,474 59.3   6,094 58.8 
Note: 92 cases (0.8%) out of originally 11,007 cases have been excluded due to missing SEP information. 
(a) Canton with organized mammography screening. 
(b) Canton without organized mammography screening. 
 
 
 
Suppl. Table 3: Contribution of invasive breast cancer cases to the pooled dataset from seven Swiss 
cancer registries (CRs) to investigate the association of socioeconomic position and breast cancer survival, 
incidence period 05/12/2000 - 31/12/2008 
CR 
all stages   with stage information  
Cases 
(N) 
Person-years 
(PY) 
% of pooled 
PY 
 
Cases 
(N) 
Person-
years (PY) 
% of 
pooled 
PY 
Fribourg (a, c) 474 2,817 2.2  460 2,737 2.3 
Geneva (a) 2,501 20,488 16.1  2,405 19,877 16.4 
Neuchâtel (b, d) 707 5,871 4.6  620 5,318 4.4 
Ticino (b) 1,773 13,856 10.9  1,712 13,174 10.8 
Valais (a) 1,458 11,410 9.0  1,393 11,022 9.1 
Vaud (a) 3,583 28,378 22.3  3,395 27,312 22.5 
Zurich (b) 5,800 44,220 34.8  5,477 42,113 34.6 
Note: 147 cases (0.9%) out of originally 16,516 cases have been excluded due to missing SEP information. From the 
remaining dataset, 73 additional cases were excluded due zero survival time (death certificate only cases or cases first 
diagnosed at autopsy). 
(a) Canton with organized mammography screening for the time period under investigation. 
(b) Canton without organized mammography screening for the time period under investigation. 
(c) Fribourg contributed cases from 01/01/2006-31/12/2008 only. 
(d) In Neuchâtel, mammography screening was implemented in 2007. Incident cases from the years 2007/2008 were 
excluded from analyses. 
